Read by QxMD icon Read


T Apaydin, H M Ozkaya, F E Keskin, O A Haliloglu, K Karababa, S Erdem, P Kadioglu
PURPOSE: To determine the differences in acromegaly diagnosis, treatment, and follow-up among Turkish endocrinologists, and to investigate how the published guidelines are applied in clinical practice. METHODS: The questionnaire was formatted as an electronic survey, conducted between November and December 2015, and sent weekly for 6 weeks via e-mail to 528 endocrinologists in Turkey. RESULTS: The questionnaire was answered by 37.4 % of endocrinologists...
October 20, 2016: Journal of Endocrinological Investigation
Adele Bahar, Zahra Kashi, Ezzatossadat Daneshpour, Ozra Akha, Shahram Ala
BACKGROUND: Cabergoline is a long-acting agonist of dopamine, which has a high affinity to dopamine receptors (type 2). Treatment using a dopaminergic agonist reduces hypothalamic stimulation that increases during liver gluconeogenesis, lipids synthesis, and insulin resistance. Our aim was to evaluate the effects of cabergoline on blood glucose levels in patients with type 2 diabetes mellitus (DM). METHODS: This study was a double-blind, controlled clinical trial in patients with type 2 DM...
October 2016: Medicine (Baltimore)
Dominik Wiedemann, Thomas Schlöglhofer, Julia Riebandt, Markus Neuner, Edda Tschernko, Heinrich Schima, Daniel Zimpfer
Peripartum cardiomyopathy requiring mechanical ciruculatory support is rare however it is a lifethreatening disease with recovery rates poorer than expected. Herein we describe a case of successfull recovery of a patient with peripartum cardiomyopathy. Implantation of a biventricular ventricular assist device was performed, additonally the patient's hyperprolactinemia was treated with Cabergoline resulting in a fast complete restoration of ventricular function.
September 22, 2016: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs
Leandro Kasuki, Evelyn de Oliveira Machado, Liana Lumi Ogino, Maria Caroline Alves Coelho, Cintia Marques Dos Santos Silva, Luiz Eduardo Armondi Wildemberg, Carlos Henrique Azeredo Lima, Mônica R Gadelha
Objective: To describe the safety and efficacy of pegvisomant therapy and the predictors of treatment response in acromegaly patients at a single tertiary reference center in Brazil. Materials and methods: We retrospectively reviewed the clinical, hormonal and radiological data of acromegaly patients treated with pegvisomant in our center. We also evaluated the presence of the d3 isoform of the growth hormone receptor (d3GHR). Results: Twenty-seven patients were included (17 women)...
October 10, 2016: Archives of Endocrinology and Metabolism
Václav Hána
Acromegaly is a rare disease caused by overproduction of growth hormone, which significantly worsens quality of life and increases morbidity and mortality of patients. Modern specialized surgery, radiosurgery, radiotherapy and pharmacotherapy substantially improved therapeutical possibilities and the perspective of patients. Current thera-peutic modalities enable to create individually tailored therapy for the specific patient and suppress the acromegalic activity. Novel forms of currently used active substances and even conceptually new forms of pharmacotherapy are under preparation and testing (eg...
2016: Vnitr̆ní Lékar̆ství
Laurent Vroonen, Patrizio Lancellotti, Monica Tomé Garcia, Raluca Dulgheru, Matilde Almanza, Ibrahima Maiga, Julien Magne, Patrick Petrossians, Renata Auriemma, Adrian F Daly, Albert Beckers
Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia...
October 5, 2016: Endocrine
Nicolás Triantafilo, Victoria Castro-Gutiérrez, Gabriel Rada
Cabergoline and bromocriptine are among the most commonly used drugs to treat prolactinoma. Cabergoline is a long-acting dopamine receptor agonist which might offer advantages over bromocriptine. However, it is not clear if this translates into clinical benefits. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified two systematic reviews including 12 studies addressing the question of this article, including five randomized controlled trials. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach...
2016: Medwave
Claudia Pivonello, Panagoula Rousaki, Mariarosaria Negri, Maddalena Sarnataro, Maria Napolitano, Federica Zito Marino, Roberta Patalano, Maria Cristina De Martino, Concetta Sciammarella, Antongiulio Faggiano, Gaetano Rocco, Renato Franco, Gregory A Kaltsas, Annamaria Colao, Rosario Pivonello
Somatostatin analogues and mTOR inhibitors have been used as medical therapy in lung carcinoids with variable results. No data are available on dopamine agonists as treatment for lung carcinoids. The main aim of the current study was to evaluate the effect of the combined treatment of somatostatin analogue octreotide and the dopamine agonist cabergoline with mTOR inhibitors in an in vitro model of typical lung carcinoids: the NCI-H727 cell line. In NCI-H727 cell line, reverse transcriptase-quantitative polymerase chain reaction and immunofluorescence were assessed to characterize the expression of the somatostatin receptor 2 and 5, dopamine receptor 2 and mTOR pathway components...
September 29, 2016: Endocrine
J C Rosa-E-Silva, G G Fortunato, Jvc Zanardi, J Meola, A A Nogueira
No abstract text is available yet for this article.
November 2015: Journal of Minimally Invasive Gynecology
Ana Espinosa De Ycaza, Alice Y Chang, Jani R Jensen, Zaraq Khan, Dana Erickson
OBJECTIVE: To describe 2 cases of macroprolactinomas with atypical presentation in women desiring pregnancy that illustrate important considerations in the management approach for macroprolactinomas in reproductive-aged women. PATIENTS: Case 1 was a 26-year-old woman referred to our institution for possible tumor resection after pituitary apoplexy during her first pregnancy. Instead, she underwent treatment with cabergoline for a year with goals of normalization of prolactin and decrease in tumor size to <1 cm before trying to conceive...
October 2015: Case Rep Womens Health
Ibrahim A Abdel-Hamid, Moustafa A Elsaied, Taymour Mostafa
Delayed ejaculation (DE) is an uncommon and a challenging disorder to treat. It is often quite concerning to patients and it can affect psychosocial well-being. Here we reviewed how DE is treated pharmacologically .We also highlighted specific settings where drugs could be introduced to medical practice. Electronic databases were searched from 1966 to February 2016, including PubMed MEDLINE, EMBASE, EBCSO Academic Search Complete, Cochrane Systematic Reviews Database, and Google Scholar using key words; delayed ejaculation, retarded ejaculation, inhibited ejaculation, drugs, treatment, or pharmacology...
August 2016: Translational Andrology and Urology
Shinya Watanabe, Hiroyoshi Akutsu, Shingo Takano, Tetsuya Yamamoto, Eiichi Ishikawa, Hiroaki Suzuki, Akira Matsumura
OBJECTIVE: Withdrawal of cabergoline is generally challenging, especially in patients with large or invasive macroprolactinomas. Therefore, we aimed to assess long-term results of cabergoline therapy for macroprolactinomas and remission achievement results after withdrawal in patients with macroprolactinomas. We also investigated clinical characteristics and factors related to remission after withdrawal. METHODS: This was an institutional review board-approved retrospective analysis...
September 21, 2016: Clinical Endocrinology
Lori Képénékian, Hélène Cebula, Frédéric Castinetti, Thomas Graillon, Thierry Brue, Bernard Goichot
OBJECTIVE: Management of macroprolactinomas has dramatically changed in recent decades, from surgical to medical treatment as first-line therapy, with the development of dopamine agonists (DA). But few data exist on the long-term outcome of these patients. PATIENTS AND METHODS: Retrospective descriptive multicenter study of patients with macroprolactinoma followed for at least 5 years between 1973 and 2008 at the University Hospitals of Strasbourg and Marseille...
September 15, 2016: Annales D'endocrinologie
Mansureh Vahdat, Maryam Kashanian, Negar Ghaziani, Narges Sheikhansari
OBJECTIVE: Myoma is one of the most common benign tumors of uterus and one of the most common causes of vaginal bleeding in women. The purpose of the present study is to evaluate the effect of dopamine receptor agonist cabergoline on the size of myoma and the amount of bleeding in the women with myoma of the uterus. STUDY DESIGN: The study was performed as a single blind randomized clinical trial on the women with symptomatic myoma. The women were randomly assigned in 2 groups...
August 9, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
Nada Yousif, Richard Z Fu, Bilal Abou-El-Ela Bourquin, Vamsee Bhrugubanda, Simon R Schultz, Barry M Seemungal
UNLABELLED: When processing sensory signals, the brain must account for noise, both noise in the stimulus and that arising from within its own neuronal circuitry. Dopamine receptor activation is known to enhance both visual cortical signal-to-noise-ratio (SNR) and visual perceptual performance; however, it is unknown whether these two dopamine-mediated phenomena are linked. To assess this, we used single-pulse transcranial magnetic stimulation (TMS) applied to visual cortical area V5/MT to reduce the SNR focally and thus disrupt visual motion discrimination performance to visual targets located in the same retinotopic space...
September 7, 2016: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
Sunita M C De Sousa, Ian M Chapman, Henrik Falhammar, David J Torpy
Dopamine agonists are the first line of therapy for prolactinomas, with high rates of biochemical control and tumour shrinkage. Toxicity is considered to be low and manageable by switching of agents and dose reduction. Dopamine agonist-induced impulse control disorders are well described in the neurology setting, but further data are required regarding this toxicity in prolactinoma patients. We performed a multicenter retrospective cohort study of eight men with prolactinomas and associated central hypogonadism...
September 6, 2016: Endocrine
James D Fett
No abstract text is available yet for this article.
August 2016: Revista Brasileira de Ginecologia e Obstetrícia
W M Drake, C E Stiles, J S Bevan, N Karavitaki, P J Trainer, D A Rees, T I Richardson, S E Baldeweg, N Stojanovic, R D Murray, A A Toogood, N M Martin, B Vaidya, T S Han, R P Steeds, F C Baldeweg, U E Sheikh, N Kyriakakis, S Parasuraman, L Taylor, N Butt, S Anyiam
: CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease; and whether current regulatory authority guidelines for echocardiographic screening are clinically appropriate. OBJECTIVE: To provide follow-up echocardiographic data on a previously described cohort of patients treated with DA for lactotrope pituitary tumors; and to explore possible associations between structural and functional valve abnormalities with the cumulative dose of drug used...
August 29, 2016: Journal of Clinical Endocrinology and Metabolism
A Oguz, D Tuzun, M Sahin, K Gul
Prolactinomas are the most common pituitary tumors but rarely seen in adolescent males. There is no indication for surgery both in micro- and macro-adenomas unless an urgent treatment is necessary. First line treatment is always medical with dopamine agonists. In this report, we presented a patient with pubertal arrest and giant prolactinoma that disappeared in a short time with cabergoline treatment.
September 2016: Nigerian Journal of Clinical Practice
Shigetoshi Yano, Takuichiro Hide, Ken Uekawa, Yumi Honda, Yoshiki Mikami, Jun-Ichi Kuratsu
BACKGROUND: A gangliocytoma rarely coexists with a pituitary adenoma in a sellar lesion. Herein, we describe our experience in treating a mixed gangliocytoma and prolactinoma of the pituitary gland. CASE DESCRIPTION: A 16-year-old male presented with severe headache and vomiting. Magnetic resonance imaging showed a large pituitary tumor with hydrocephalus. Because of the increased levels of serum prolactin (PRL), we treated the patient with cabergoline, which decreased the tumor size and improved the hydrocephalus...
August 13, 2016: World Neurosurgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"